论文部分内容阅读
在发现金刚烷胺治疗流感有效之后,近来又发现病毒唑(ribavirin或virazol)治疗流感有明显的疗效。 1984年9～12月美国微生物学和免疫学中心GilBert等用双盲法研究了病毒唑小颗粒气溶胶治疗甲流感A/victoria/7/83(H_1N_1)新抗原变异株的38名患者,18例用病毒唑气溶胶治疗,20例用无菌水气溶胶作对照,在68小时住院治疗中,患者在42小时内接受总量为2.4克病毒唑,而未出现任何副作用,气溶胶平均含有190微克病毒唑/每升空气,其流动率12.5升/分钟,气溶胶粒直径为1.6微米,病人入院后立即开始治
The discovery of ribavirin or virazol has also been shown to have a significant effect on the flu, after finding that amantadine is effective in treating the flu. From September to December 1984, GilBert, a center of American microbiology and immunology, studied the 38 patients with ribavirin particle aerosol treatment of the novel antigenic variant of influenza A / victoria / 7/83 (H_1N_1) by double-blind method. 18 With ribavirin aerosol treatment, 20 cases were treated with sterile aqueous aerosol. In a 68-hour hospitalization, patients received a total of 2.4 grams of ribavirin within 42 hours without any side effects. The average aerosol content was 190 μg ribavirin per liter of air at a flow rate of 12.5 liters per minute with an aerosol particle diameter of 1.6 μm and the patient started treatment immediately after admission